Venture Life Group PLC UK Bond Network presentation
November 23 2017 - 5:14AM
RNS Non-Regulatory
TIDMVLG
Venture Life Group PLC
23 November 2017
23 November 2017
VENTURE LIFE GROUP PLC
("Venture Life" or "the Company")
UK Bond Network presentation
Venture Life Group plc (AIM: VLG), the international consumer
self-care group focused on developing, manufacturing and
commercialising products for the ageing population, announces it
will be presenting at the upcoming UK Bond Network ("UKBN")
investor event on Tuesday 28 November. The UKBN enables
sophisticated, high net worth and professional investors to invest
in bonds issued by quoted and unquoted British businesses. The
event, in partnership with NEX Exchange and international law firm
CMS, will feature three of UKBN's previous bond issuing businesses
- and potentially a new listed borrower - each with a 15-minute
slot to present their company.
Sharon Collins, Commercial Director of Venture Life Group will
be giving an update on the Company to both existing and potential
bondholders.
The event will take place at the NEX Exchange, 2 Broadgate
Circle, London EC2M 7UR and will begin at 5.30pm. To register for
the presentation, please use the following link:
https://www.eventbrite.co.uk/e/uk-bond-network-investor-evening-tickets-38491614455
+44 (0) 1344
Venture Life Group PLC 578 004
Jerry Randall, Chief Executive Officer
Adrian Crockett, Chief Financial Officer
Walbrook PR venturelife@walbrookpr.com
or + 44 (0) 20 7933 8780
Anna Dunphy / Paul McManus +44 (0) 7876 741 001 /
+44 (0) 7980 541 893
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the ageing population. The Group's product portfolio includes
some key products such as the UltraDEX oral care products range,
food supplements for lowering cholesterol and maintaining brain
function, medical devices for women's intimate healthcare and
haemorrhoids and dermo-cosmetics for addressing the signs of
ageing.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies supplied by the Group's international distribution
partners.
Through its Development & Manufacturing business in Italy,
Biokosmes, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic
sectors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABBBDBIGDBGRX
(END) Dow Jones Newswires
November 23, 2017 06:14 ET (11:14 GMT)
Venture Life (LSE:VLG)
Historical Stock Chart
From Apr 2024 to May 2024
Venture Life (LSE:VLG)
Historical Stock Chart
From May 2023 to May 2024